Journal
Cancer chemotherapy and pharmacology
Publication Date
4-1-2022
Volume
89
Issue
4
First Page
487
Last Page
497
Document Type
Open Access Publication
DOI
10.1007/s00280-022-04406-6
Rights and Permissions
Bagegni, N.A., Park, H., Kraft, K. et al. Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors. Cancer Chemother Pharmacol 89, 487–497 (2022). https://doi.org/10.1007/s00280-022-04406-6. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Recommended Citation
Bagegni, Nusayba A; Park, Haeseong; Kraft, Katlyn; O-Toole, Maura; Gao, Feng; Waqar, Saiama N; Ratner, Lee; Morgensztern, Daniel; Devarakonda, Siddhartha; Amin, Manik; Baggstrom, Maria Q; Liang, Chris; Selvaggi, Giovanni; and Wang-Gillam, Andrea, "Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors." Cancer chemotherapy and pharmacology. 89, 4. 487 - 497. (2022).
https://digitalcommons.wustl.edu/oa_4/3125
Department
ICTS (Institute of Clinical and Translational Sciences)
